NO20061184L - Fremgangsmater og blandinger for behandling av herpes-infeksjoner - Google Patents

Fremgangsmater og blandinger for behandling av herpes-infeksjoner

Info

Publication number
NO20061184L
NO20061184L NO20061184A NO20061184A NO20061184L NO 20061184 L NO20061184 L NO 20061184L NO 20061184 A NO20061184 A NO 20061184A NO 20061184 A NO20061184 A NO 20061184A NO 20061184 L NO20061184 L NO 20061184L
Authority
NO
Norway
Prior art keywords
methods
compositions
treatment
herpes infections
immunoglobulins
Prior art date
Application number
NO20061184A
Other languages
English (en)
Norwegian (no)
Inventor
Klaus-Peter Radtke
Ulrich Betz
Original Assignee
Talecris Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Talecris Biotherapeutics Inc filed Critical Talecris Biotherapeutics Inc
Publication of NO20061184L publication Critical patent/NO20061184L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20061184A 2003-09-05 2006-03-14 Fremgangsmater og blandinger for behandling av herpes-infeksjoner NO20061184L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/656,781 US6984492B2 (en) 2003-09-05 2003-09-05 Methods and compositions for treating herpes infections
PCT/US2004/028559 WO2005025617A2 (en) 2003-09-05 2004-09-02 Methods and compositions for treating herpes infections

Publications (1)

Publication Number Publication Date
NO20061184L true NO20061184L (no) 2006-06-01

Family

ID=34226428

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061184A NO20061184L (no) 2003-09-05 2006-03-14 Fremgangsmater og blandinger for behandling av herpes-infeksjoner

Country Status (13)

Country Link
US (3) US6984492B2 (sk)
EP (1) EP1663309A2 (sk)
JP (1) JP2007504268A (sk)
KR (1) KR20060107509A (sk)
CN (1) CN1845756A (sk)
AU (1) AU2004272001A1 (sk)
BR (1) BRPI0414139A (sk)
CA (1) CA2537360A1 (sk)
IL (1) IL173805A0 (sk)
NO (1) NO20061184L (sk)
NZ (1) NZ546303A (sk)
WO (2) WO2005023303A1 (sk)
ZA (1) ZA200602738B (sk)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2248825E (pt) * 2009-05-04 2013-01-07 Ribovax Biotechnologies Sa Fragmentos de antigénio ligantes a um anticorpo para uso no tratamento e diagnóstico de doenças oculares
WO2013023362A1 (zh) * 2011-08-16 2013-02-21 深圳市卫武光明生物制品有限公司 静注巨细胞病毒人免疫球蛋白及其制备方法
EP2912060B1 (en) * 2012-10-29 2019-12-25 The University of North Carolina at Chapel Hill Compositions and methods for inhibiting pathogen infection
US10829543B2 (en) 2012-10-29 2020-11-10 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting pathogen infection
CA2942166A1 (en) 2014-03-03 2015-09-11 Albert Einstein College Of Medicine, Inc. Recombinant herpes simplex virus 2 (hsv-2) vaccine vectors
US10918712B2 (en) 2014-03-03 2021-02-16 Albert Einstein College Of Medicine Passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors
CA2950489C (en) 2014-06-26 2022-09-20 Heidelberg Immunotherapeutics Gmbh Topical application for an anti-hsv antibody
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
WO2017083681A1 (en) 2015-11-13 2017-05-18 The University Or North Carolina At Chapel Hill Optimized crosslinkers for trapping a target on a substrate
CN105532575A (zh) * 2016-01-14 2016-05-04 中国科学院昆明动物研究所 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
CA3118367A1 (en) * 2018-11-08 2020-05-14 The Board Of Trustees Of The University Of Illinois Treatment and diagnosis of autoantibody-mediated eye diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617379A (en) * 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
US4665159A (en) * 1985-11-07 1987-05-12 Miles Laboratories, Inc. High titer varicella-zoster immune globulin for intravenous administration
US4717564A (en) * 1985-11-07 1988-01-05 Miles Laboratories, Inc. High titer varicella-zoster immune globulin for intravenous administration
US5258177A (en) * 1991-12-10 1993-11-02 Alpha Therapeutic Corporation IgA preparation and process of making the same
RU2051054C1 (ru) 1992-04-14 1995-12-27 Московский научно-исследовательский институт эпидемиологии и микробиологии им.Г.Н.Габричевского Способ получения препарата противогерпетического иммуноглобулина человека
CA2153661A1 (en) * 1993-01-12 1994-07-21 Anthony George Gristina Methods and compositions for the direct concentrated delivery of passive immunity
US5681565A (en) * 1993-01-12 1997-10-28 Medical Sciences Research Institute Methods and compositions for passive immunotherapy
AU6968098A (en) * 1997-04-15 1998-11-11 Advanced Viral Research Corp. Topical treatment of skin diseases and eye afflictions
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies

Also Published As

Publication number Publication date
US6984492B2 (en) 2006-01-10
IL173805A0 (en) 2006-07-05
ZA200602738B (en) 2008-06-25
US20090232798A1 (en) 2009-09-17
WO2005025617A3 (en) 2005-05-26
WO2005025617A2 (en) 2005-03-24
KR20060107509A (ko) 2006-10-13
CA2537360A1 (en) 2005-03-24
CN1845756A (zh) 2006-10-11
NZ546303A (en) 2009-03-31
US20060198848A1 (en) 2006-09-07
WO2005023303A1 (en) 2005-03-17
JP2007504268A (ja) 2007-03-01
US20050053605A1 (en) 2005-03-10
AU2004272001A1 (en) 2005-03-24
EP1663309A2 (en) 2006-06-07
BRPI0414139A (pt) 2006-10-31

Similar Documents

Publication Publication Date Title
NO20061184L (no) Fremgangsmater og blandinger for behandling av herpes-infeksjoner
CY1120977T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
WO2003096989A3 (en) Anti tubercular drug: compositions and methods
WO2004006842A3 (en) Combinations of drugs for the treatment of neoplasms
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
LTC1620113I2 (lt) Ivermektino topinė kompozicija, skirta dermatologinių susirgimų gydymui
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
NO20034549D0 (no) Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV
NO994256D0 (no) SmÕ molekyler som er anvendelige ved behandling av inflamasjonssykdom
WO1999052515A3 (de) Verwendung von phosphororganischen verbindungen zur therapeutischen und prophylaktischen behandlung von infektionen
MY155218A (en) Small molecules useful in the treatment of inflammatory disease
WO2004002999A8 (en) Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
NO20052362D0 (no) Fremgangsmater for administrering av dalbavancin for behandling av bakterielle infeksjoner
DK1151009T3 (da) Antimikrobielt/endotoksin-neutraliserende polypeptid
MXPA05004697A (es) Soluciones farmaceuticas que comprenden un compuesto modafinil y uso para la fabricacion de un medicamento para tratar diferentes enfermedades.
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
DE60108489D1 (de) Kombinationstherapien mit gefässschädigender aktivität
PT1150704E (pt) Melagatran para o tratamento da inflamacao
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
WO2005081972A3 (en) Maleiimide anti-tumor phosphatase inhibitors
WO2005080549A3 (de) Trioxacarcine und deren verwendung gegen infektionskrankheiten
AU2003237088A1 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
WO2005053613A3 (en) Combinations for the treatment of fungal infections

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application